Aptose Biosciences Inc. (APTOF)
OTCMKTS
· Delayed Price · Currency is USD
1.620
+0.020 (1.25%)
At close: Dec 5, 2025
Aptose Biosciences Employees
Aptose Biosciences had 13 employees as of December 31, 2024. The number of employees decreased by 23 or -63.89% compared to the previous year.
Employees
13
Change (1Y)
-23
Growth (1Y)
-63.89%
Revenue / Employee
n/a
Profits / Employee
-$1,484,154
Market Cap
4.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| Zomedica | 152 |
Aptose Biosciences News
- 4 hours ago - Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations - GlobeNewsWire
- 17 days ago - Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical - GlobeNewsWire
- 22 days ago - Aptose Reports Third Quarter 2025 Results - GlobeNewsWire
- 7 weeks ago - Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML - GlobeNewsWire
- 3 months ago - Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor - GlobeNewsWire
- 3 months ago - Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial - GlobeNewsWire
- 4 months ago - Aptose Reports Second Quarter 2025 Results - GlobeNewsWire
- 4 months ago - Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy - GlobeNewsWire